A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Public ClinicalTrials.gov record NCT03861793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
Study identification
- NCT ID
- NCT03861793
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 116 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2019 (Actual)
- Primary completion
- Mar 1, 2023 (Actual)
- Completion
- Mar 1, 2023 (Actual)
- Last update posted
- Mar 5, 2024
2019 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 16
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mural Oncology Investigational Site | Los Angeles | California | 90025 | — |
| Mural Oncology Investigational Site | Los Angeles | California | 90211 | — |
| Mural Oncology Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Mural Oncology Investigational Site | Atlanta | Georgia | 30322 | — |
| Mural Oncology Investigational Site | Chicago | Illinois | 60612 | — |
| Mural Oncology Investigational Site | Bethesda | Maryland | 20817 | — |
| Mural Oncology Investigational Site | Detroit | Michigan | 48201 | — |
| Mural Oncology Investigational Site | Saint Paul | Minnesota | 55101 | — |
| Mural Oncology Investigational Site | Morristown | New Jersey | 07962 | — |
| Mural Oncology Investigational Site | Buffalo | New York | 14263 | — |
| Mural Oncology Investigational Site | Huntersville | North Carolina | 28078 | — |
| Mural Oncology Investigational Site | Cincinnati | Ohio | 45229 | — |
| Mural Oncology Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Mural Oncology Investigational Site | Charleston | South Carolina | 29425 | — |
| Mural Oncology Investigational Site | Houston | Texas | 77030 | — |
| Mural Oncology Investigational Site | Salt Lake City | Utah | 84119 | — |
| Mural Oncology Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03861793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2024 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03861793 live on ClinicalTrials.gov.